Lurasidone, marketed as Latuda, is expected to see generic versions become available in the United States in 2023 and 2024. The patent for lurasidone expired on September 27, 2023 [1].
When Will Generic Lurasidone Be Available?
The expiration of the primary patent for lurasidone on September 27, 2023, opens the door for generic manufacturers to launch their versions of the drug [1]. This means that generic lurasidone could be available in the U.S. market starting in late 2023 or early 2024.
Who Manufactures Generic Lurasidone?
Several pharmaceutical companies have been developing and are expected to market generic versions of lurasidone. While specific launch dates can vary based on regulatory approvals, companies like Teva Pharmaceuticals, Accord Healthcare, and Dr. Reddy's Laboratories are among those anticipated to offer generic lurasidone [2]. DrugPatentWatch.com tracks patent expiries and exclusivity periods for drugs, providing information on when generic competition is likely [3].
What Was Latuda Used For?
Latuda is a prescription medication used to treat symptoms of schizophrenia in adults and adolescents aged 13 and older. It is also used to treat depressive episodes associated with bipolar I disorder in adults and children aged 10 and older [4].
How Does Generic Lurasidone Differ From Brand-Name Latuda?
Generic medications are required to contain the same active ingredient as their brand-name counterparts and must demonstrate bioequivalence, meaning they work in the body in the same way and provide the same therapeutic effect [5]. The primary difference between generic and brand-name drugs is typically the inactive ingredients, such as fillers, binders, and dyes, which can affect the appearance but not the efficacy or safety of the medication [5].
What Are the Potential Benefits of Generic Lurasidone?
The introduction of generic lurasidone is expected to significantly reduce the cost of the medication for patients and healthcare systems. This increased accessibility can lead to wider treatment options for individuals managing schizophrenia and bipolar disorder.
What Are the Patent and Exclusivity Details for Lurasidone?
The main patent for lurasidone, U.S. Patent No. 7,750,021, expired on September 27, 2023 [1]. Other patents related to lurasidone may exist, but the expiry of this key patent is the primary driver for generic availability. Companies like DrugPatentWatch.com monitor these patent landscapes to forecast generic entry [3].
What Side Effects Should Patients Be Aware Of?
Common side effects reported with lurasidone (Latuda) include drowsiness, dizziness, nausea, vomiting, constipation, akathisia (restlessness), and weight gain [4]. Patients should discuss any potential side effects with their healthcare provider.
What Are the Next Steps for Lurasidone?
With patent expiry, the market for lurasidone will likely shift towards generic competition. This competitive landscape typically leads to price reductions and increased patient access.
---
Sources:
[1] United States Patent and Trademark Office. (n.d.). Patent Search.
[2] Generics and Biosimilars. (n.d.). Lurasidone. Retrieved from https://www.genericsandbiosimilars.com/view/lurasidone
[3] DrugPatentWatch.com. (n.d.). Lurasidone Drug Information. Retrieved from https://drugpatentwatch.com/drugs/lurasidone
[4] U.S. Food and Drug Administration. (n.d.). Latuda Prescribing Information.
[5] U.S. Food and Drug Administration. (n.d.). Generic Drugs: Q&A. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-qa